AM-1241

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
AM-1241
(IUPAC) ime
(2-jodo-5-nitrofenil)-[1-[(1-metilpiperidin-2-il)metil]indol-3-il]metanon
Klinički podaci
Identifikatori
CAS broj 444912-48-5
ATC kod nije dodeljen
PubChem[1][2] 10141893
ChemSpider[3] 8317404
ChEMBL[4] CHEMBL408430 YesY
Hemijski podaci
Formula C22H22IN3O3 
Mol. masa 503,333 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status Legal

AM-1241 (1-(metilpiperidin-2-ilmetil)-3-(2-jodo-5-nitrobenzoil)indol) je jedinjenje iz aminoalkilindolne familije koje deluje kao potentan i selektivan agonist za kanabinoidni receptor CB2,[5][6] sa Ki od 3,4 nM na CB2 i 80x selektivnošću u odnosu na srodni CB1 receptor.[7][8] On ima analgetsko dejstvo u životinjskim studijama, posebno protiv „atipičnog“ bola kao što su hiperalgezija i alodinija.[9] Smatra se da je to dejstvo posredovano putem CB2 perifernog otpuštanja endogenih opioidnih peptida,[10] kao i direktne aktivacije TRPA1 kanala.[11] On je takođe pokazao efikasnost u tretmanu amiotrofične lateralne skleroze u životinjskim modelima.[12][13]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  5. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, Meyer MD (September 2006). "In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?". British Journal of Pharmacology 149 (2): 145–54. PMC 2013801. PMID 16894349. doi:10.1038/sj.bjp.0706838. 
  6. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y, Strassle BW, Cummons TA, Piesla MJ, Harrison JE, Whiteside GT, Kennedy JD (August 2007). "Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers". British Journal of Pharmacology 151 (7): 1061–70. PMC 2042933. PMID 17549048. doi:10.1038/sj.bjp.0707303. 
  7. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP (September 2003). "Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS". Proceedings of the National Academy of Sciences of the United States of America 100 (18): 10529–33. PMC 193595. PMID 12917492. doi:10.1073/pnas.1834309100. 
  8. Marriott KS, Huffman JW (2008). "Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor". Current Topics in Medicinal Chemistry 8 (3): 187–204. PMID 18289088. doi:10.2174/156802608783498014. 
  9. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A (March 2006). "CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms". The European Journal of Neuroscience 23 (6): 1530–8. PMID 16553616. doi:10.1111/j.1460-9568.2006.04684.x. 
  10. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP (February 2005). "CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids". Proceedings of the National Academy of Sciences of the United States of America 102 (8): 3093–8. PMC 549497. PMID 15705714. doi:10.1073/pnas.0409888102. 
  11. Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM (January 2008). "Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation". Journal of Neuroscience 28 (5): 1064–75. PMID 18234885. doi:10.1523/JNEUROSCI.1565-06.2008. 
  12. Kim K, Moore DH, Makriyannis A, Abood ME (August 2006). "AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis". European Journal of Pharmacology 542 (1-3): 100–5. PMID 16781706. doi:10.1016/j.ejphar.2006.05.025. 
  13. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL (April 2007). "The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset". Journal of Neurochemistry 101 (1): 87–98. PMC 2819701. PMID 17241118. doi:10.1111/j.1471-4159.2006.04346.x. 

Vidi još[uredi - уреди | uredi izvor]